| Literature DB >> 23737906 |
Yan Zhang1, Lixin Li, Cheng Xiang, Zhiqian Ma, Tian Ma, Shuchai Zhu.
Abstract
The aim of this in vivo study was to explore the protective properties of melatonin against Adriamycin-induced myocardial toxicity. A rat model of breast cancer was established and the rats were randomly divided into the blank group (Blank), the solvent group [Diss; dehydrated alcohol: physiological saline (1:9)], the Adriamycin group (ADM), the melatonin group (MLT) and the melatonin + Adriamycin group (M+A). The concentrations of lipid peroxide (LPO), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in myocardial tissues were detected, the changes in myocardial tissues were observed using light microscopy and electron microscopy, and the 1-month survival rates of each group of rats were compared. Breast cancer was established in 116 rats. In the ADM group, the concentration of LPO was higher and the concentrations of SOD and GSH-Px were significantly lower than those in the blank group. In the M+A group, compared with the ADM group, the concentration of LPO was lower (P<0.05) and the concentrations of SOD and GSH-Px were higher (P<0.05). It was observed using light and electron microscopy that the myocardial injuries to the M+A group were significantly alleviated in comparison with those in the ADM group; the 1-month survival rate in the M+A group was higher than that in the ADM group. Melatonin may have a protective role in the myocardium by reducing Adriamycin-induced myocardial oxidative damage.Entities:
Keywords: Adriamycin; breast cancer; cardiotoxicity; melatonin
Year: 2013 PMID: 23737906 PMCID: PMC3671825 DOI: 10.3892/etm.2013.989
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparison of LPO, SOD and GSH-Px concentrations in the various groups.
| Groups | LPO (nmol/mgPr) | SOD ( | GSH-Px ( |
|---|---|---|---|
| Blank | 6.68±0.91 | 26.67±2.13 | 17.33±2.17 |
| Diss | 7.15±0.44 | 25.33±4.49 | 16.54±1.91 |
| MLT | 5.59±1.77 | 26.55±2.07 | 18.02±0.75 |
| ADM | 9.88±1.50 | 10.19±0.78 | 8.97±0.57 |
| M+A | 6.79±0.48 | 19.99±1.91 | 13.81±1.52 |
t=5.557, P= 0.025 vs. ADM group;
t=−13.99, P=0.029 vs. ADM group;
t=−8.462, P=0.014 vs. ADM group. Blank, no intervention; Diss, solvent intervention; MLT, melatonin intervention; ADM, Adriamycin intervention; M+A, melatonin + Adriamycin intervention; LPO, lipid peroxide; SOD, superoxide dismutase; GSH-Px, glutathione peroxidase.
Figure 1(A) Adriamycin-induced myocardial injuries and muscle bundle fractures were visible under a light microscope with low magnification in the ADM group (magnification, ×100); (B) Adriamycin-induced myocardial mucinous degeneration was visible under a light microscope with high magnification in the ADM group (magnification, ×400); (C) Adriamycin-induced organelle injuries in myocardial cells and serious mitochondrial cavitation were visible under a light microscope with high magnification in the ADM group (magnification, ×20.0KX); (D) Essentially normal cardiac muscles were visible under a light microscope with low magnification in the M+A group (magnification, ×100); (E) Only mild granular changes were visible under a light microscope with high magnification in the M+A group (magnification, 400×); (F) Adriamycin-induced organelle injuries in myocardial cells and serious mitochondrial cavitation were visible under an electron microscope with high magnification in the M+A group (magnification, ×20,000). Blank, no intervention; Diss, solvent intervention; MLT, melatonin intervention; ADM, Adriamycin intervention; M+A, melatonin + Adriamycin intervention.
Comparison of 1-month survival rate among groups.
| Groups | n | One month survival (n) |
|---|---|---|
| Blank | 16 | 4 |
| Diss | 16 | 6 |
| MLT | 14 | 14 |
| ADM | 16 | 5 |
| M+A | 14 | 11 |
Blank and Diss: χ2=1.45, P=0.35; Blank and MLT: χ2=17.5, P=0.000; Blank and ADM: χ2=0.00, P=1.00; Blank and M+A: χ2=8.57, P=0.005; MLT and M+A: χ2=3.36, P=0.1; ADM and M+A: χ2=6.71, P=0.012. Blank, no intervention; Diss, solvent intervention; MLT, melatonin intervention; ADM, Adriamycin intervention; M+A, melatonin + Adriamycin intervention.